SADS Live interview with Thryv Therapeutics

All of us at Thryv Therapeutics Inc. are excited that three of our team were invited to join Dr. Michael Ackerman as part of the SADS Live program.

During this live interview, our Chief Medical Officer Dr. Philip Sager, Founder and Key Consultant Dr. Saumya Das of Massachusetts General Hospital, and Paul F. Truex, our Chief Executive Officer, discussed our efforts to bring new therapies to people with Long QT Syndrome and explored what drives us to challenge the status quo of current LQTS treatments.

This is part of the introduction by Dr. Michael Ackerman:

“I’m going to take you on a journey of one possible therapy for tomorrow and how it came about, from the point of discovery to the development of a new company. Then the next steps required to prove that molecule you developed might work, what pre-clinical steps the FDA requires for us to demonstrate we have a drug that works, that’s safe and worthy of an FDA approval.”

To learn more about Thryv Therapeutics’ passionate team and progress, what the next steps are as we move into clinical studies, and what we are doing to challenge the current LQTS treatments, please watch this interview recorded on January 20, 2023:

The SADS Foundation is a community of families, medical professionals, and supporters saving lives and advancing care for people with heart arrhythmia conditions that can lead to sudden death. On their website you’ll find a community of understanding, support and guidance from others navigating life with a SADS condition sads.org